136 related articles for article (PubMed ID: 22484930)
1. Urinary volatile compounds as biomarkers for lung cancer.
Hanai Y; Shimono K; Matsumura K; Vachani A; Albelda S; Yamazaki K; Beauchamp GK; Oka H
Biosci Biotechnol Biochem; 2012; 76(4):679-84. PubMed ID: 22484930
[TBL] [Abstract][Full Text] [Related]
2. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
3. Quantitative breath analysis of volatile organic compounds of lung cancer patients.
Song G; Qin T; Liu H; Xu GB; Pan YY; Xiong FX; Gu KS; Sun GP; Chen ZD
Lung Cancer; 2010 Feb; 67(2):227-31. PubMed ID: 19409642
[TBL] [Abstract][Full Text] [Related]
4. Confounding effect of benign pulmonary diseases in selecting volatile organic compounds as markers of lung cancer.
Wang M; Sheng J; Wu Q; Zou Y; Hu Y; Ying K; Wan H; Wang P
J Breath Res; 2018 Sep; 12(4):046013. PubMed ID: 30102249
[TBL] [Abstract][Full Text] [Related]
5. A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis.
Chen X; Xu F; Wang Y; Pan Y; Lu D; Wang P; Ying K; Chen E; Zhang W
Cancer; 2007 Aug; 110(4):835-44. PubMed ID: 17599760
[TBL] [Abstract][Full Text] [Related]
6. A novel polyaniline/polypyrrole/graphene oxide fiber for the determination of volatile organic compounds in headspace gas of lung cell lines.
Li J; Xu H
Talanta; 2017 May; 167():623-629. PubMed ID: 28340770
[TBL] [Abstract][Full Text] [Related]
7. Identification of urine biomarkers associated with lung adenocarcinoma.
Wang W; Wang S; Zhang M
Oncotarget; 2017 Jun; 8(24):38517-38529. PubMed ID: 28404947
[TBL] [Abstract][Full Text] [Related]
8. The volatilome - investigation of volatile organic metabolites (VOM) as potential tumor markers in patients with head and neck squamous cell carcinoma (HNSCC).
Opitz P; Herbarth O
J Otolaryngol Head Neck Surg; 2018 Jul; 47(1):42. PubMed ID: 29970175
[TBL] [Abstract][Full Text] [Related]
9. Detection of Volatile Organic Compounds (VOCs) in Urine via Gas Chromatography-Mass Spectrometry QTOF to Differentiate Between Localized and Metastatic Models of Breast Cancer.
Woollam M; Teli M; Angarita-Rivera P; Liu S; Siegel AP; Yokota H; Agarwal M
Sci Rep; 2019 Feb; 9(1):2526. PubMed ID: 30792417
[TBL] [Abstract][Full Text] [Related]
10. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines.
Wang Y; Hu Y; Wang D; Yu K; Wang L; Zou Y; Zhao C; Zhang X; Wang P; Ying K
Cancer Biomark; 2012; 11(4):129-37. PubMed ID: 23144150
[TBL] [Abstract][Full Text] [Related]
11. Identification of volatile metabolites in human saliva from patients with oral squamous cell carcinoma via zeolite-based thin-film microextraction coupled with GC-MS.
Shigeyama H; Wang T; Ichinose M; Ansai T; Lee SW
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1104():49-58. PubMed ID: 30445287
[TBL] [Abstract][Full Text] [Related]
12. Application of an artificial neural network model for selection of potential lung cancer biomarkers.
Ligor T; Pater Ł; Buszewski B
J Breath Res; 2015 May; 9(2):027106. PubMed ID: 25944812
[TBL] [Abstract][Full Text] [Related]
13. In situ detection of lung cancer volatile fingerprints using bronchoscopic air-sampling.
Santonico M; Lucantoni G; Pennazza G; Capuano R; Galluccio G; Roscioni C; La Delfa G; Consoli D; Martinelli E; Paolesse R; Di Natale C; D'Amico A
Lung Cancer; 2012 Jul; 77(1):46-50. PubMed ID: 22264635
[TBL] [Abstract][Full Text] [Related]
14. Application of Urinary Volatile Organic Compounds (VOCs) for the Diagnosis of Prostate Cancer.
Gao Q; Su X; Annabi MH; Schreiter BR; Prince T; Ackerman A; Morgas S; Mata V; Williams H; Lee WY
Clin Genitourin Cancer; 2019 Jun; 17(3):183-190. PubMed ID: 30853355
[TBL] [Abstract][Full Text] [Related]
15. Effect of chemotherapy on urinary volatile biomarkers for lung cancer by HS-SPME-GC-MS and chemometrics.
Rubio-Sánchez R; Ríos-Reina R; Ubeda C
Thorac Cancer; 2023 Dec; 14(36):3522-3529. PubMed ID: 37945317
[TBL] [Abstract][Full Text] [Related]
16. Optimization of volatile markers of lung cancer to exclude interferences of non-malignant disease.
Zou Y; Zhang X; Chen X; Hu Y; Ying K; Wang P
Cancer Biomark; 2014; 14(5):371-9. PubMed ID: 25171479
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive breath analysis of pulmonary nodules.
Peled N; Hakim M; Bunn PA; Miller YE; Kennedy TC; Mattei J; Mitchell JD; Hirsch FR; Haick H
J Thorac Oncol; 2012 Oct; 7(10):1528-33. PubMed ID: 22929969
[TBL] [Abstract][Full Text] [Related]
18. Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells.
Sponring A; Filipiak W; Ager C; Schubert J; Miekisch W; Amann A; Troppmair J
Cancer Biomark; 2010; 7(3):153-61. PubMed ID: 21263191
[TBL] [Abstract][Full Text] [Related]
19. Glycosylated Alpha-1-acid glycoprotein 1 as a potential lung cancer serum biomarker.
Ayyub A; Saleem M; Fatima I; Tariq A; Hashmi N; Musharraf SG
Int J Biochem Cell Biol; 2016 Jan; 70():68-75. PubMed ID: 26563422
[TBL] [Abstract][Full Text] [Related]
20. Investigation of lung cancer biomarkers by hyphenated separation techniques and chemometrics.
Buszewski B; Ulanowska A; Kowalkowski T; Cieśliński K
Clin Chem Lab Med; 2011 Oct; 50(3):573-81. PubMed ID: 22035139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
